Salem Capital Management Inc. maintained its position in Eli Lilly and Co. (NYSE:LLY) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 6,067 shares of the company’s stock at the end of the third quarter. Salem Capital Management Inc.’s holdings in Eli Lilly and were worth $487,000 as of its most recent SEC filing.
Other institutional investors have also bought and sold shares of the company. Eaton Vance Management increased its position in Eli Lilly and by 72.3% in the second quarter. Eaton Vance Management now owns 5,498,527 shares of the company’s stock valued at $433,009,000 after buying an additional 2,307,920 shares in the last quarter. Beutel Goodman & Co Ltd. bought a new position in Eli Lilly and during the second quarter valued at about $104,345,000. Janus Capital Management LLC increased its position in Eli Lilly and by 15.9% in the second quarter. Janus Capital Management LLC now owns 10,021,381 shares of the company’s stock valued at $789,162,000 after buying an additional 1,377,814 shares in the last quarter. Vanguard Group Inc. increased its position in Eli Lilly and by 2.2% in the second quarter. Vanguard Group Inc. now owns 63,236,677 shares of the company’s stock valued at $4,979,889,000 after buying an additional 1,350,329 shares in the last quarter. Finally, Bank of Montreal Can bought a new position in Eli Lilly and during the second quarter valued at about $86,545,000. 75.11% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Eli Lilly and Co. (NYSE:LLY) traded up 1.65% during mid-day trading on Friday, reaching $69.12. 8,620,682 shares of the company were exchanged. Eli Lilly and Co. has a 12 month low of $64.18 and a 12 month high of $88.16. The firm has a market capitalization of $73.11 billion, a PE ratio of 30.07 and a beta of 0.28. The company’s 50 day moving average price is $76.69 and its 200 day moving average price is $77.92.
Eli Lilly and (NYSE:LLY) last posted its earnings results on Tuesday, October 25th. The company reported $0.88 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.96 by $0.08. The firm had revenue of $5.19 billion for the quarter, compared to analyst estimates of $4.23 billion. Eli Lilly and had a net margin of 11.73% and a return on equity of 23.71%. The company’s revenue for the quarter was up 4.7% on a year-over-year basis. During the same period in the previous year, the firm earned $0.89 earnings per share. Equities analysts anticipate that Eli Lilly and Co. will post $3.55 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, December 9th. Shareholders of record on Tuesday, November 15th will be paid a dividend of $0.51 per share. This represents a $2.04 dividend on an annualized basis and a yield of 2.95%. The ex-dividend date of this dividend is Thursday, November 10th. Eli Lilly and’s payout ratio is 88.70%.
LLY has been the subject of several research analyst reports. Argus upped their price objective on shares of Eli Lilly and from $90.00 to $95.00 and gave the company a “buy” rating in a research note on Tuesday, August 2nd. Morgan Stanley set a $73.00 target price on shares of Eli Lilly and and gave the stock a “hold” rating in a research note on Thursday. Zacks Investment Research upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $92.00 target price for the company in a research note on Friday, August 5th. BMO Capital Markets reiterated an “outperform” rating and set a $94.00 target price on shares of Eli Lilly and in a research note on Tuesday, September 27th. Finally, Goldman Sachs Group Inc. upgraded shares of Eli Lilly and from a “neutral” rating to a “buy” rating and increased their target price for the stock from $89.00 to $95.00 in a research note on Tuesday, September 27th. Four equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $108.95.
In other news, insider Maria A. Crowe sold 2,248 shares of the company’s stock in a transaction that occurred on Wednesday, October 5th. The shares were sold at an average price of $81.37, for a total value of $182,919.76. Following the completion of the sale, the insider now directly owns 94,319 shares of the company’s stock, valued at approximately $7,674,737.03. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 0.20% of the company’s stock.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.